International AIDS Vaccine Initiative-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:International AIDS Vaccine Initiative - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014038
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
International AIDS Vaccine Initiative (IAVI) is a not-for-profit organization that develops preventive HIV vaccine candidates. The organization offers vaccine development through basic research, discovery, preclinical evaluation and manufacturing, and regulatory review, among others. It also conducts policy analysis and performs vaccine trials and epidemiological research. IAVI’s product portfolio includes mRNA-NFL, BG505 Envelope, eOD Immunogen, AAV-PG9, AD26, MVA, protein and CDV replicating vector, among others. The organization partners with academic, industry and government organizations and clinical research center. It operates in South Africa, Kenya, India, the US, and the Netherlands. IAVI is headquartered in New York, the US.

International AIDS Vaccine Initiative – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
International AIDS Vaccine Initiative, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
International AIDS Vaccine Initiative, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
International AIDS Vaccine Initiative, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
International AIDS Vaccine Initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
International AIDS Vaccine Initiative, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
International AIDS Vaccine Initiative, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
International AIDS Vaccine Partners with CureVac 10
IAVI, GlycoMimetics, And Glycosensors and Diagnostics Enter Into Agreement To Develop AIDS Vaccine 11
Lipoxen Extends Co-Development Agreement With IAVI 12
Licensing Agreements 13
Valneva Enters Into Licensing Agreement With International AIDS Vaccine Initiative For HIV Vaccine 13
DNAVEC Enters Into Licensing Agreement With International AIDS Vaccine Initiative For Prophylactic AIDS Vaccine 14
International AIDS Vaccine Initiative – Key Competitors 15
International AIDS Vaccine Initiative – Key Employees 16
International AIDS Vaccine Initiative – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Government and Public Interest 18
Sep 08, 2016: New Vaccination Strategies Successfully Coach Immune System to Make Powerful HIV-Neutralizing Antibodies 18
Product News 20
May 19, 2016: New HIV-Mimicking Particles That Trigger Immune Response Could Advance AIDS Vaccine Design 20
Mar 24, 2016: New findings in humans provide encouraging foundation for upcoming AIDS vaccine clinical trial 21
Jan 15, 2016: Study Provides Additional Insights for AIDS Vaccine Design 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
International AIDS Vaccine Initiative, Pharmaceuticals & Healthcare, Key Facts 2
International AIDS Vaccine Initiative, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
International AIDS Vaccine Initiative, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
International AIDS Vaccine Initiative, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
International AIDS Vaccine Initiative, Deals By Therapy Area, 2011 to YTD 2017 8
International AIDS Vaccine Initiative, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
International AIDS Vaccine Partners with CureVac 10
IAVI, GlycoMimetics, And Glycosensors and Diagnostics Enter Into Agreement To Develop AIDS Vaccine 11
Lipoxen Extends Co-Development Agreement With IAVI 12
Valneva Enters Into Licensing Agreement With International AIDS Vaccine Initiative For HIV Vaccine 13
DNAVEC Enters Into Licensing Agreement With International AIDS Vaccine Initiative For Prophylactic AIDS Vaccine 14
International AIDS Vaccine Initiative, Key Competitors 15
International AIDS Vaccine Initiative, Key Employees 16
International AIDS Vaccine Initiative, Other Locations 17

★海外企業調査レポート[International AIDS Vaccine Initiative-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Highmark Inc-製薬・医療分野:企業M&A・提携分析
    Summary Highmark Inc (Highmark), a subsidiary of Highmark Health, is a provider of healthcare insurance solutions. The company underwrites various indemnities and offers healthcare insurance products to individuals, families, groups, companies and federal employees. In addition, the company provides …
  • Daito Trust Construction Co., Ltd.:企業の戦略・SWOT・財務情報
    Daito Trust Construction Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daito Trust Construction Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Guess?, Inc.:戦略・SWOT・企業財務分析
    Guess?, Inc. - Strategy, SWOT and Corporate Finance Report Summary Guess?, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Volkswagen Financial Services AG:戦略・SWOT・企業財務分析
    Volkswagen Financial Services AG - Strategy, SWOT and Corporate Finance Report Summary Volkswagen Financial Services AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Mesoblast Ltd (MSB):製薬・医療:M&Aディール及び事業提携情報
    Summary Mesoblast Ltd (Mesoblast) is a regenerative medicine company, which develops regenerative cell-based products. Its pipeline product candidates include MPC-150-IM, which is under development for the treatment of chronic congestive heart failure; MSC-100-IV, for the treatment of acute graft ve …
  • Toyo Suisan Kaisha, Ltd. (2875):企業の財務・戦略的SWOT分析
    Toyo Suisan Kaisha, Ltd. (2875) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Genesis Energy, L.P.:企業の戦略・SWOT・財務分析
    Genesis Energy, L.P. - Strategy, SWOT and Corporate Finance Report Summary Genesis Energy, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • JX Nippon Oil & Gas Exploration Corp Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    JX Nippon Oil & Gas Exploration Corp Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary JX Nippon Oil & Gas Exploration Corp Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that o …
  • Co-operative Group Ltd:企業の戦略・SWOT・財務分析
    Co-operative Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Co-operative Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Tubacero S. de RL de CV:企業の戦略・SWOT・財務情報
    Tubacero S. de RL de CV - Strategy, SWOT and Corporate Finance Report Summary Tubacero S. de RL de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Cleveland BioLabs Inc (CBLI)-医療機器分野:企業M&A・提携分析
    Summary Cleveland BioLabs Inc (Cleveland) is a biopharmaceutical company that develops and commercializes drugs to treat cancer, orphan indications and protect healthy tissues from radiation and chemotherapy. The company’s product includes entolimod, a recombinant protein which acts as an agonist of …
  • Georgetown University:製薬・医療:M&Aディール及び事業提携情報
    Summary Georgetown University (GU) is an academic and research institute that offers educational services. The university provides undergraduate and graduate degree programs in the fields of law, medical, medical residencies, business administration and public policy degrees, post-doctoral positions …
  • Reliance Worldwide Corporation Ltd (RWC):企業の財務・戦略的SWOT分析
    Reliance Worldwide Corporation Ltd (RWC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Advanced Accelerator Applications SA (AAAP):企業の財務・戦略的SWOT分析
    Summary Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company’s lead product candidate comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnas …
  • Byco Petroleum Pakistan Ltd (BYCO):企業の財務・戦略的SWOT分析
    Byco Petroleum Pakistan Ltd (BYCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Croatia Airlines d.d.:企業の戦略・SWOT・財務情報
    Croatia Airlines d.d. - Strategy, SWOT and Corporate Finance Report Summary Croatia Airlines d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Tata Global Beverages Limited:企業のM&A・事業提携・投資動向
    Tata Global Beverages Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tata Global Beverages Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Concert Pharmaceuticals Inc (CNCE):製薬・医療:M&Aディール及び事業提携情報
    Summary Concert Pharmaceuticals Inc (Concert Pharmaceuticals) is a clinical stage biotechnology company which discovers and develops small molecule drugs. The company develops its products using its deuterated chemical entity (DCE) platform to develop novel therapeutics for autoimmune and inflammato …
  • Lin Bioscience Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Lin Bioscience Inc (Lin Bioscience) is a drug development company that specializes in developing therapies for oncology, ophthalmology and other metabolic diseases. The company’s pipeline product LBS-008 is an oral therapy for treatment of macular degeneration; LBS-007 is a small molecular i …
  • DiscGenics Inc-製薬・医療分野:企業M&A・提携分析
    Summary DiscGenics Inc (DiscGenics) is a biotechnology company that develops advanced spinal therapeutics. The company develops therapies to treat patients with intervertebral disc diseases. Its products comprise Injectable Discogenic Cell Therapy (IDCT), developed for treating patients with moderat …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆